01158nas a2200193   4500000000100000008004100001260001300042653001600055653001100071653001200082653002900094100001600123700001500139245010300154300001100257490000700268520067500275022001400950       1992                            d  c1992 Oct10aClofazimine10aHumans10aleprosy10aMycobacterium Infections1 aFreerksen E1 aSeydel J K00aCritical comments on the treatment of leprosy and other mycobacterial infections with clofazimine.  a1243-50 v423 a<p>The usefulness of clofazimine (CLO, CAS 2030-63-9) in the treatment of mycobacterial infections with special emphasis on treatment of leprosy is critically discussed. Skin discolouration which decreases compliance, placenta passage, excretion in mother's milk which endanger the embryo or baby respectively, saturation kinetics in absorption and difficulties to determine free drug concentration are severe problems. The observed antagonism in the combination of CLO with other drugs, especially with dapsone, is another argument against its application in the therapy of mycobacterial infections. In Germany CLO has not been approved by the Bundesgesundheitsamt.</p>  a0004-4172